2seventy bio Inc (MEX:TSVT)
MXN 170 0 (0%) Market Cap: 3.70 Bil Enterprise Value: 4.92 Bil PE Ratio: 0 PB Ratio: 1.08 GF Score: 44/100

2Seventy Bio Inc Introduction to 2seventy's Pipeline and Next-Gen Multiple Myeloma Strategy Conference Call Transcript

Sep 21, 2021 / 03:00PM GMT
Operator

Good day, and thank you for standing by. Welcome to the 2seventy bio Research Deep Dive Session One Conference Call.

(Operator Instructions)

I would now like to hand the conference over to your speaker today, Nick Leschly, Chief Kairos Officer, 2seventy bio.

Nick Leschly
bluebird bio, Inc. - President, CEO & Director

Thank you very much. I appreciate it. And I appreciate everyone joining us here this morning for a bit of an unusual session in the sense that typically we just jump into Q&A and do a typical investor discussion. In this case, we thought it made more sense -- as we're launching 2seventy here in the coming weeks, we thought it was good to sort of dive in, in more detail into a number of things that we're up to. So that's what this session is all about. We really appreciate all of you joining. And if you flip to the agenda slide, here on Slide 2, you can see it's a bit of an aggressive agenda, but we are trying to get through the material in sort of one run so we can focus on questions for each of you as you want to dig

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot